Commitments and Contingencies (Details Narrative)
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
|
Nov. 03, 2020 |
Feb. 27, 2023
USD ($)
|
Oct. 19, 2019 |
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Jun. 30, 2023
USD ($)
|
Mar. 31, 2023
USD ($)
|
Sep. 30, 2022
USD ($)
|
Jun. 30, 2022
USD ($)
|
Mar. 31, 2022
USD ($)
|
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Sep. 30, 2023
EUR (€)
shares
|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2023
EUR (€)
shares
|
| Amount payable for services rendered |
|
|
|
|
|
|
|
|
|
$ 428,669
|
|
|
|
| Payments For Future Research And Collobration |
|
|
|
$ 1,290,177
|
|
|
|
|
|
1,290,177
|
|
|
|
| Aggerate Amount Payable, Description |
under the agreement will be completed by the end of the fourth quarter 2023 at a total cost to the Company of up to $4.2 million
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amount may be payable by Company in future periods for services rendered |
|
|
|
354,850
|
|
|
|
|
|
354,850
|
|
|
|
| Accrued compensation expense |
|
|
|
603,465
|
|
|
|
|
|
603,465
|
|
|
|
| Royalty Payment |
|
|
|
0
|
|
|
$ 2,911
|
|
|
0
|
|
$ 2,911
|
|
| Share-based Payment Arrangement, Noncash Expense |
|
|
|
537,980
|
$ 592,174
|
$ 693,657
|
$ 639,075
|
$ 854,304
|
$ 915,031
|
1,823,811
|
|
$ 2,408,410
|
|
| Long-term debt payable |
|
|
|
3,344,393
|
|
|
|
|
|
3,344,393
|
|
|
|
| Grant Repyable |
|
|
|
$ 482,835
|
|
|
|
|
|
482,835
|
|
|
|
| First Insurance Funding |
|
$ 356,258
|
|
|
|
|
|
|
|
|
|
|
|
| Fixed Interest Rate |
|
7.42%
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity Date |
|
November 2023
|
|
|
|
|
|
|
|
|
|
|
|
| Principal balance payable |
|
$ 79,168
|
|
|
|
|
|
|
|
|
|
|
|
| Recognized total compensation expense |
|
|
|
|
|
|
|
|
|
$ 961,535
|
|
|
|
| In 2016 [Member] | ING [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
May 2031
|
May 2031
|
|
|
| Fixed Interest Rate On Lease |
|
|
|
2.62%
|
|
|
|
|
|
2.62%
|
|
|
2.62%
|
| Lease Payable |
|
|
|
$ 441,669
|
|
|
|
|
|
$ 441,669
|
|
|
|
| Purchase of property | € |
|
|
|
|
|
|
|
|
|
|
|
|
€ 1,120,000
|
| In 2010 [Member] | Walloon Region Government [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amount Repayable |
|
|
|
26,467
|
|
|
|
|
|
$ 26,467
|
|
|
|
| Repayment Of Grants | € |
|
|
|
|
|
|
|
|
|
|
|
|
314,406
|
| Terms Of Agreement Description |
|
|
|
|
|
|
|
|
|
it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6.00% royalty on revenue, is equal to twice the amount of funding received
|
it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6.00% royalty on revenue, is equal to twice the amount of funding received
|
|
|
| Grant Receivable | € |
|
|
|
|
|
|
|
|
|
|
|
|
1,050,000.00
|
| In 2018 [Member] | Tamu [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt conversion, Converted instrument, Rate |
|
|
7.50%
|
|
|
|
|
|
|
|
|
|
|
| Additional interest |
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
| Equity Interest |
|
|
12.50%
|
|
|
|
|
|
|
|
|
|
|
| Equity interest in Volition Vet |
|
|
|
|
|
|
|
|
|
12.50%
|
12.50%
|
|
|
| In 2018 [Member] | Walloon Region Government [Member] | Colorectal Cancer Research Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amount Repayable |
|
|
|
105,823
|
|
|
|
|
|
$ 105,823
|
|
|
|
| Repayment Of Grants | € |
|
|
|
|
|
|
|
|
|
|
|
|
181,500
|
| Terms Of Agreement Description |
|
|
|
|
|
|
|
|
|
it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received
|
it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received
|
|
|
| Grant Receivable | € |
|
|
|
|
|
|
|
|
|
|
|
|
605,000
|
| Grant Repaid By Installments |
|
|
|
|
|
|
|
|
|
over 12 years
|
over 12 years
|
|
|
| In 2020 [Member] | Walloon Region Government [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amount Repayable |
|
|
|
253,345
|
|
|
|
|
|
$ 253,345
|
|
|
|
| Repayment Of Grants | € |
|
|
|
|
|
|
|
|
|
|
|
|
278,830
|
| Terms Of Agreement Description |
|
|
|
|
|
|
|
|
|
it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received
|
it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received
|
|
|
| Grant Receivable | € |
|
|
|
|
|
|
|
|
|
|
|
|
929,433
|
| Grant Repaid By Installments |
|
|
|
|
|
|
|
|
|
over 15 years
|
over 15 years
|
|
|
| In 2020 [Member] | Walloon Region Government [Member] | Colorectal Cancer Research Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amount Repayable |
|
|
|
97,200
|
|
|
|
|
|
$ 97,200
|
|
|
|
| Repayment Of Grants | € |
|
|
|
|
|
|
|
|
|
|
|
|
148,500
|
| Terms Of Agreement Description |
|
|
|
|
|
|
|
|
|
it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received
|
it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received
|
|
|
| Grant Receivable | € |
|
|
|
|
|
|
|
|
|
|
|
|
€ 495,000
|
| Grant Repaid By Installments |
|
|
|
|
|
|
|
|
|
over 10 years
|
over 10 years
|
|
|
| Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional Cost Of Company |
|
|
|
|
|
|
|
|
|
$ 582,135
|
|
|
|
| Collaborative Obligations Amount Due |
|
|
|
0
|
|
|
|
|
|
0
|
|
|
|
| August Two Thousand Twenty Three [Member] | Guy's and St Thomas' NHS Foundation Trust [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional Cost Of Company |
|
|
|
|
|
|
|
|
|
198,042
|
|
|
|
| Collaborative Obligations Amount Due |
|
|
|
$ 0
|
|
|
|
|
|
0
|
|
|
|
| September 30, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recognized total compensation expense |
|
|
|
|
|
|
|
|
|
5,494
|
|
|
|
| RSUs vested in 2024 |
|
|
|
|
|
|
|
|
|
363,120
|
|
|
|
| RSUs vested in 2025 |
|
|
|
|
|
|
|
|
|
364,601
|
|
|
|
| RSUs vested in 2026 |
|
|
|
|
|
|
|
|
|
365,085
|
|
|
|
| Unrecognized compensation expense |
|
|
|
|
|
|
|
|
|
$ 1,092,806
|
|
|
|
| 2015 Plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price per share | $ / shares |
|
|
|
$ 5.00
|
|
|
|
|
|
$ 5.00
|
|
|
|
| Stock option granted shares | shares |
|
|
|
1,000,000
|
|
|
|
|
|
1,000,000
|
|
|
1,000,000
|
| Restricted stock option granted shares | shares |
|
|
|
500,000
|
|
|
|
|
|
500,000
|
|
|
500,000
|
| Restricted stock option approved granted shares | shares |
|
|
|
|
|
|
|
|
|
1,569,000
|
1,569,000
|
|
|
| Restricted stock option approved granted shares in exchange for services | shares |
|
|
|
|
|
|
|
|
|
450,000
|
450,000
|
|
|
| 2015 Plan | October 31 2022 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock option granted shares | shares |
|
|
|
1,144,000
|
|
|
|
|
|
1,144,000
|
|
|
1,144,000
|
| Managing Director's Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amount payable |
|
|
|
$ 207
|
|
|
|
|
|
$ 207
|
|
|
|
| Royalty Payment |
|
|
|
|
|
|
|
|
|
$ 116,453
|
|
|
|
| Royality |
|
|
|
|
|
|
|
|
|
6.00%
|
6.00%
|
|
|
| Loan Agreement [Member] | In 2016 [Member] | ING [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
15 years
|
15 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 270,000
|
|
|
| Fixed Interest Rate |
|
|
|
2.62%
|
|
|
|
|
|
2.62%
|
|
|
2.62%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
December 2031
|
December 2031
|
|
|
| Principal Balance Payable |
|
|
|
$ 172,523
|
|
|
|
|
|
$ 172,523
|
|
|
|
| Loan Agreement [Member] | In 2016 [Member] | Namur Invest [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
7 years
|
7 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 440,000
|
|
|
| Fixed Interest Rate |
|
|
|
4.85%
|
|
|
|
|
|
4.85%
|
|
|
4.85%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
December 2023
|
December 2023
|
|
|
| Total Long-term Debt |
|
|
|
$ 27,619
|
|
|
|
|
|
$ 27,619
|
|
|
|
| Loan Agreement [Member] | In 2017 [Member] | SOFINEX [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
7 years
|
7 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 1,000,000
|
|
|
| Fixed Interest Rate |
|
|
|
4.50%
|
|
|
|
|
|
4.50%
|
|
|
4.50%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
September 2024
|
September 2024
|
|
|
| Total Long-term Debt |
|
|
|
$ 317,599
|
|
|
|
|
|
$ 317,599
|
|
|
|
| Drawn down amount | € |
|
|
|
|
|
|
|
|
|
|
|
|
€ 1,000,000
|
| Loan Agreement [Member] | In 2019 [Member] | Namur Invest [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
4 years
|
4 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 500,000
|
|
|
| Fixed Interest Rate |
|
|
|
4.80%
|
|
|
|
|
|
4.80%
|
|
|
4.80%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
September 2024
|
September 2024
|
|
|
| Total Long-term Debt |
|
|
|
$ 173,421
|
|
|
|
|
|
$ 173,421
|
|
|
|
| Loan Agreement [Member] | In 2020 [Member] | Namur Invest [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
10 years
|
10 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 830,000
|
|
|
| Fixed Interest Rate |
|
|
|
4.00%
|
|
|
|
|
|
4.00%
|
|
|
4.00%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
March 2031
|
March 2031
|
|
|
| Principal Balance Payable |
|
|
|
$ 697,313
|
|
|
|
|
|
$ 697,313
|
|
|
|
| Loan Agreement [Member] | 2022 [Member] | Long-term Debt [Member] | First Insurance Funding [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
4 years
|
4 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 1,000,000.0
|
|
|
| Fixed Interest Rate |
|
|
|
6.00%
|
|
|
|
|
|
6.00%
|
|
|
6.00%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
July 2026
|
July 2026
|
|
|
| Principal Balance Payable |
|
|
|
$ 897,254
|
|
|
|
|
|
$ 897,254
|
|
|
|
| Loan Agreement [Member] | 2022 [Member] | Namur [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
4 years
|
4 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 500,000
|
|
|
| Fixed Interest Rate |
|
|
|
5.45%
|
|
|
|
|
|
5.45%
|
|
|
5.45%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
December 2027
|
December 2027
|
|
|
| Principal Balance Payable |
|
|
|
$ 529,332
|
|
|
|
|
|
$ 529,332
|
|
|
|
| Loan Agreement [Member] | June 2023 [Member] | Namur Invest [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
4 years
|
4 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 400,000
|
|
|
| Loan Drawn Down Amount | € |
|
|
|
|
|
|
|
|
|
|
|
|
€ 200,000
|
| Fixed Interest Rate |
|
|
|
7.00%
|
|
|
|
|
|
7.00%
|
|
|
7.00%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
June 2027
|
June 2027
|
|
|
| Principal Balance Payable |
|
|
|
$ 211,733
|
|
|
|
|
|
$ 211,733
|
|
|
|
| Clinical Study Research Agreement [Member] | In 2018 [Member] | University of Taiwan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Obligations Amount Due |
|
|
|
510,000
|
|
|
|
|
|
510,000
|
|
|
|
| Collaborative Obligations Amount |
|
|
|
2,550,000
|
|
|
|
|
|
2,550,000
|
|
|
|
| Operating Lease Right of Use Obligations [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating Lease Right-of-use Assets |
|
|
|
490,468
|
|
|
|
|
|
490,468
|
|
|
|
| Operating Lease Liabilities |
|
|
|
$ 518,729
|
|
|
|
|
|
$ 518,729
|
|
|
|
| Weighted Average Discount Rate |
|
|
|
2.63%
|
|
|
|
|
|
2.63%
|
|
|
2.63%
|
| Payment Of Lease Liabilities |
|
|
|
|
|
|
|
|
|
$ 190,825
|
|
|
|
| Weighted average remaining lease term |
|
|
|
|
|
|
|
|
|
24 months
|
24 months
|
|
|
| Operating Lease Expense |
|
|
|
|
|
|
|
|
|
$ 192,030
|
|
|
|
| Short Term Lease Costs |
|
|
|
|
|
|
|
|
|
$ 53,077
|
|
|
|
| Namur Innovation and Growth [Member] | Loan Agreement [Member] | In 2021 [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan Agreement Term |
|
|
|
|
|
|
|
|
|
3 years
|
3 years
|
|
|
| Repayment Of Long-term Loan Amount | € |
|
|
|
|
|
|
|
|
|
|
€ 450,000
|
|
|
| Fixed Interest Rate |
|
|
|
5.00%
|
|
|
|
|
|
5.00%
|
|
|
5.00%
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
June 2025
|
June 2025
|
|
|
| Total Long-term Debt |
|
|
|
$ 317,599
|
|
|
|
|
|
$ 317,599
|
|
|
|
| Restricted Stock Units [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price per share | $ / shares |
|
|
|
$ 5.00
|
|
|
|
|
|
$ 5.00
|
|
|
|
| Recognized total compensation expense |
|
|
|
|
|
|
|
|
|
$ 522,195
|
|
|
|
| RSU Vested in 2023 |
|
|
|
|
|
|
|
|
|
260,249
|
|
|
|
| RSU Vested in 2025 |
|
|
|
|
|
|
|
|
|
179,091
|
|
|
|
| Unrecognized compensation expense |
|
|
|
|
|
|
|
|
|
623,561
|
|
|
|
| Performance Based Award [Member] | Vest In 2023 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Unrecognized compensation expense |
|
|
|
|
|
|
|
|
|
350
|
|
|
|
| Share-based Payment Arrangement, Noncash Expense |
|
|
|
|
|
|
|
|
|
901,059
|
|
|
|
| Performance Based Award [Member] | Vest In 2024 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Unrecognized compensation expense |
|
|
|
|
|
|
|
|
|
331
|
|
|
|
| Share-based Payment Arrangement, Noncash Expense |
|
|
|
|
|
|
|
|
|
$ 758,708
|
|
|
|